The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Jason Hassenstab
Project Title: Psychometric Analyses of ARC Smartphone-based Cognitive Assessments
Date: December 23, 2025 at 3:20 pm
Request ID: D2555
Aim 1: Determine if there variation in ability levels visible using a modern psychometrics score that is obscured with the standard total score.
Aim 2: Conduct factor analyses of traditional cognitive testing data together with ARC test data.
Aim 3:
Aim 4:
Investigator: Michael Scholl
Project Title: Progression rates to tau-PET positivity and cognitive impairment risk in preclinical Alzheimer’s disease
Date: December 19, 2025 at 9:10 am
Request ID: D2556
Aim 1: To determine progression to tau-PET positivity in amyloid-β (Aβ)–positive, cognitively unimpaired (CU) individuals based on the FDA/EMA-approved visual interpretation method of [18F]flortaucipir PET.
Aim 2: To assess subsequent clinical progression in Aβ+CU individuals with initially negative tau-PET scans.
Aim 3:
Aim 4:
Investigator: Jeanne Latourelle
Project Title: Mechanistic Discovery and Validation of Causal Drivers in Alzheimer’s Disease Using Gemini Digital Twins and Knight-ADRC Multi-Omic Data
Date: December 9, 2025 at 3:18 pm
Request ID: D2552
Aim 1: Construction of Gemini Digital Twins in a hypothesis-free approach to characterize molecular and cellular mechanisms underlying Alzheimer’s disease progression and identify causal drivers of disease related phenotypes within and beyond the ATN framework.
Aim 2: Evaluate and validate causal drivers of disease related phenotypes that were previously identified from existing Gemini Digital Twin models to assess robustness and generalizability across cohorts.
Aim 3:
Aim 4:
Investigator: Cecilia Lee
Project Title: Ophthalmic Data Analysis for Better Understanding of Alzheimer’s and Related Dementias
Date: December 3, 2025 at 2:49 pm
Request ID: D2551
Aim 1: Outline ophthalmic health profiles (e.g., diagnoses of AMD, glaucoma, diabetic retinopathy, cataract) among ADRC participants by linking participant identifiers with their longitudinal EHR data.
Aim 2: Examine associations between ophthalmic diagnoses and established ADRC biomarkers, including structural MRI, PET (amyloid/tau), CSF and plasma markers (e.g. Aβ, p-tau 217, GFAP, NfL), as well as cognitive outcomes
Aim 3: Assess whether ophthalmic health independently predicts biomarker-positive Alzheimer’s disease, cognitive decline, or conversion to dementia after adjusting for demographics, vascular risk factors, and APOE status.
Aim 4: Establish a foundation for future use of retinal scans with ADRC as a non-invasive biomarker to monitor brain health
Investigator: Tammie Benzinger
Project Title: Impact of Freesurfer (7.3) Editing on Brain Volume and PET-SUVR Measurements
Date: December 1, 2025 at 10:35 am
Request ID: D2550
Aim 1: To identify differences in regional brain volumes, mean cortical PET SUVr, and tau PET burden between scans that have undergone manual FreeSurfer editing and those processed without edits
Aim 2:
Aim 3:
Aim 4:
Investigator: Gareth Williams
Project Title: Analysis of CSF/blood plasma proteomics variation across those over 60 years old in conjunction with amyloid PET imaging
Date: November 28, 2025 at 7:32 am
Request ID: D2554
Aim 1: To compare independent data sets of CSF/blood plasma data related to Alzheimer’s pathology. Specifically, the PMID: 30775436 study that established a predictive framework for PET Abeta positivity.
Aim 2: Build case for effective cohort size in a future study of BBB integrity and Dementia risk.
Aim 3:
Aim 4:
Investigator: Prof. Nicolas Langer
Project Title: Modulators of the Amyloid–Tau Relationship: A Multi-Cohort Analysis of Age, Sex, and APOE4 Status
Date: November 24, 2025 at 1:58 am
Request ID: D2553
Aim 1: Characterizing how age, APOE4 genotype, and sex interact to shape the relationship between amyloid and tau pathologies
Aim 2:
Aim 3:
Aim 4:
Investigator: Tharick Pascoal
Project Title: Comparison of CT-based and MR-based processing for tau PET regional quantification
Date: November 13, 2025 at 4:29 pm
Request ID: D2549
Aim 1: We aim to develop and validate a PET-CT–based quantification pipeline that repurposes the CT acquired with PET as anatomical reference, eliminating the need for PET-to-MR registration while maintaining quantitative accuracy.
Aim 2:
Aim 3:
Aim 4:
Investigator: MARCO AIELLO
Project Title: Multimodal relationship between microstructural and functional markers of dementia
Date: November 13, 2025 at 3:28 am
Request ID:
Aim 1: To investigate the role of microstructural patterns as early marker of neurodegeneration
Aim 2: To investigate the mutual relationship between microstructure and PET imaging markers
Aim 3:
Aim 4:
Investigator: Dimitri Mantovani
Project Title: Multi-Cohort Tau-PET Evaluation Across the Alzheimer’s Continuum: APOE Genotype-Stratified Analysis
Date: November 3, 2025 at 2:35 pm
Request ID: D2548
Aim 1: Evaluate if APOE ε4 homozygotes exhibit an earlier and faster accumulation of tau pathology compared to ε3 homozygotes, even after accounting for amyloid burden
Aim 2: Evaluate the spatial distribution of tau accumulation differs by APOE genotype, with ε4 carriers showing earlier involvement of limbic and association cortices
Aim 3: Evaluate if APOE ε4–related acceleration of tau deposition mediates earlier cognitive decline, bridging the gap between sporadic AD and genetically determined forms such as autosomal dominant AD and Down syndrome
Aim 4: